Sudden cardiac death: Investigation of the classical risk factors in a community-based hypertrophic cardiomyopathy cohort

Hellenic Journal of Cardiology

Volumn 54, Issue 4, 2013, Pages 281-288

  Anastasakis, Aris ^a   Theopistou, Artemisia ^a   Rigopoulos, Angelos ^a   Kotsiopoulou, Christina ^a   Georgopoulos, Stavros ^a   Fragakis, Konstantinos ^a   Sevdalis, Elias ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Hypertrophic cardiomyopathy; Prognosis; Risk factors; Sudden cardiac death

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; SOTALOL; VERAPAMIL;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CHILD; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PROSPECTIVE STUDY; RISK FACTOR; SUDDEN CARDIAC DEATH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; CHILD, PRESCHOOL; DEATH, SUDDEN, CARDIAC; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; EXERCISE TEST; FEMALE; GREECE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84881056748     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Parcharidis G. How knowing the genetics affects management of cardiomyopathy. Hellenic J Cardiol. 2012; 53: 331-332.
2. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003; 349: 1064-1075.
3. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J. 2003; 24: 1965-1991.
4. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363 (9424): 1881-1891.
5. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol. 1993; 72: 970-972.
6. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000; 36: 2212-2218.
7. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001; 357: 420-424.
8. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999; 281: 650-655.
9. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol. 1995; 26: 1529-1536.
10. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol. 2003; 41: 987-993.
11. Kyriakidis M, Triposkiadis F, Anastasakis A, et al. Hypertro-phic cardiomyopathy in Greece: clinical course and outcome. Chest. 1998; 114: 1091-1096.
12. Kofflard MJ, Waldstein DJ, Vos J, ten Cate FJ. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol. 1993; 72: 939-943.
13. Jääskeläinen P, Soranta M, Miettinen R, et al. The cardiac beta-myosin heavy chain gene is not the predominant gene for hypertrophic cardiomyopathy in the Finnish population. J Am Coll Cardiol. 1998; 32: 1709-1716.
14. Miliou A, Anastasakis A, D'Cruz LG, et al. Low prevalence of cardiac troponin T mutations in a Greek hypertrophic cardiomyopathy cohort. Heart. 2005; 91: 966-967.
15. Prasad K, Atherton J, Smith GC, McKenna WJ, Frenneaux MP, Nihoyannopoulos P.: Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy. Heart 1999; 82 Suppl 3: III8-III15.
16. Parcharidis G. Hypertrophic cardiomyopathy: what have we learned in fifty years? Hellenic J Cardiol. 2011; 52: 285-286.
17. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008; 29: 270-276.
18. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart. 1997; 77: 130-132.
19. Sharma S, Elliott PM, Whyte G, et al. Utility of metabolic ex-ercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol. 2000; 36: 864-870.
20. Anastasakis A, Kotsiopoulou C, Rigopoulos A, et al. Similarities in the profile of cardiopulmonary exercise testing between patients with hypertrophic cardiomyopathy and strength athletes. Heart 2005; 91: 1477-1478.
21. Cox DR, Oakes D. Analysis of survival data. London: Chap-man and Hall; 1984
22. Rubin DB. Multiple imputation after 18+ years. Journal of the American Statistical Association. 1996; 91: 473-489.
23. Schafer JL. Analysis of incomplete multivariate data. New York: Chapman and Hall, 1997.
24. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000; 342: 1778-1785.
25. Elliott P, McKenna W. The science of uncertainty and the art of probability: syncope and its consequences in hypertrophic cardiomyopathy. Circulation. 2009; 119: 1697-1699.
26. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003; 42: 873-879.
27. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation. 1994; 90: 2743-2747.
28. Koga Y, Itaya K, Toshima H. Prognosis in hypertrophic cardiomyopathy. Am Heart J. 1984; 108: 351-359.
29. Maron BJ, Schiffers A, Klues HG. Comparison of phenotypic expression of hypertrophic cardiomyopathy in patients from the United States and Germany. Am J Cardiol. 1999; 83: 626-7, A10.
30. Gatzoulis KA, Archontakis S, Dilaveris P, et al. Ventricular arrhythmias: from the electrophysiology laboratory to clinical practice. Part II: potentially malignant and benign ventricular arrhythmias. Hellenic J Cardiol. 2012; 53: 217-233.